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Abstract
 
Phosphoinositide 3-kinase (PI3K) is thought to contribute to the pathogenesis of asthma by
effecting the recruitment, activation, and apoptosis of inflammatory cells. We examined the
role of class IA PI3K in antigen-induced airway inflammation and hyperresponsiveness by i.p.
administration into mice of 
 
 
 
p85 protein, a dominant negative form of the class IA PI3K regu-
latory subunit, p85
 
 
 
, which was fused to HIV-TAT (TAT-
 
 
 
p85). Intraperitoneal administration
of TAT-
 
 
 
p85 caused time-dependent transduction into blood leukocytes, and inhibited activated
phosphorylation of protein kinase B (PKB), a downstream target of PI3K, in lung tissues in
mice receiving intranasal FMLP. Antigen challenge elicited pulmonary infiltration of lymphocytes,
eosinophils and neutrophils, increase in mucus-containing epithelial cells, and airway hyperre-
sponsiveness to methacholine. Except for modest airway neutrophilia, these effects all were
blocked by treatment with 3–10 mg/kg of TAT-
 
 
 
p85. There was also significant reduction in
IL-5 and IL-4 secretion into the BAL. Intranasal administration of IL-5 caused eosinophil
migration into the airway lumen, which was attenuated by systemic pretreatment with TAT-
 
 
 
p85. We conclude that PI3K has a regulatory role in Th2-cell cytokine secretion, airway
inflammation, and airway hyperresponsiveness in mice.
Key words: allergy • cytokines • eosinophils • lung • inﬂammation
 
Introduction
 
Persistent inflammation of the airway and subsequent airway
hyperresponsiveness are fundamental characteristics of bron-
chial asthma (1). Th2 lymphocytes mediate the inflammatory
response in human asthma; mRNA expression for IL-4 and
IL-5 and the presence of these cytokines in the airway are
correlated to disease severity (2, 3). Th2 cytokine secretion
is chemotactic for eosinophils, which release bronchoactive
lipids, e.g., leukotriene C
 
4
 
 (LTC
 
4
 
) (4), platelet-activating
factor (PAF) (5), and granular proteins (e.g., major basic
protein) after migration into airways (6). The major basic
protein of eosinophils causes bronchial hyperresponsiveness
and sloughing of the airway epithelium (7).
Phosphoinositide 3-kinase (PI3K) is a signal transduction
enzyme, which phosphorylates the D3 position of the inositol
ring of phosphoinositide and its phosphorylated derivatives
(8). The class IA PI3K is activated by tyrosine kinases and
consists of a heterodimer composed of a 110-kD (p110
 
 
 
,
 
 
 
, 
 
 
 
) catalytic subunit and an adaptor protein (p85
 
 
 
, p85
 
 
 
,
p55
 
 
 
, p55
 
 
 
, p50
 
 
 
) (9). Recent studies suggest that PI3K
may contribute to the pathogenesis of asthma by effecting
the recruitment, activation, and apoptosis of inflammatory
cells (10, 11). Class IA PI3K plays a key role in induction of
the Th2 response (10–14). PI3K is also essential for IL-5–
induced eosinophil release from bone marrow (12) and the
migration of eosinophils caused by a number of chemoattrac-
tants (13). The catalytic subunits p110
 
 
 
 and p110
 
 
 
 modulate
Fc
 
 
 
R1-dependent mast cell activation (15). In addition to
inflammatory cells, smooth-muscle cell mitogenesis and
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hyperplasia are also regulated by PI3K (14, 16). Enhanced
basal activity of PI3K has been reported in eosinophils de-
rived from allergic asthmatics (17). However, the determi-
nation of the precise role of class IA PI3K has been difficult
because (a) knockout mice lacking p85
 
 
 
 and its splicing
variants die within a few weeks after birth (18) and (b) this
deletion results in immunodeficiency caused by B cell dys-
function (19).
Recent investigations have demonstrated the usefulness
of in vivo transduction of TAT-fusion proteins in mice
(20). This allows for introduction of functional proteins di-
rectly in the intracellular compartment of all cells in rodents
within 2 h. Transcellular administration (transduction) of
dominant negative inhibitors accordingly can block en-
zyme systems otherwise requiring knockout and allow for
immediate assessment, thus avoiding lethal mutations.
In these studies, we transduced dominant negative p85
 
 
 
(
 
 
 
p85) (21) using an HIV-TAT protein transduction
(PTD) domain into mice in vivo. In contrast to wild-type
p85
 
 
 
 (Wp85), 
 
 
 
p85 lacks the binding site for the catalytic
p110 subunit (21). We constructed a 
 
 
 
p85 plasmid
(pTAT-
 
 
 
p85) containing 6 His residues, 11 amino acids of
TAT, 
 
 
 
p85, and purified TAT-
 
 
 
p85 fusion protein (Fig. 1
a). We tested the hypothesis that class IA PI3K mediates
both antigen-induced airway inflammation and airway hy-
perresponsiveness to methacholine. We found that trans-
duction of TAT-
 
 
 
p85 into mice inhibited protein kinase B
(PKB, also termed Akt) phosphorylation in lung tissues and
that TAT-
 
 
 
p85 blocked antigen-induced airway inflam-
mation and hyperresponsiveness, and reduced Th2 cyto-
kine level in BAL.
 
Materials and Methods
 
Generation of TAT-
 
 
 
p85 and Its In Vivo Administration.
 
A
cDNA fragment encoding dominant negative p85
 
 
 
 was amplified
by PCR from the 
 
 
 
p85 cDNA with the deletion of 35 amino ac-
ids from residues 478–513 with the insertion of two amino acids
in pGEX (provided by Dr. M. Kasuga) with the following prim-
ers (sense: 5
 
 
 
-ACC GGT ATG AGT GCC GAG GGG TAC
CAG TAC-3
 
 
 
; antisense: 5
 
 
 
-GAATTCTCATCGCCTCTGCT-
GCGCGTACACTGGGT-3
 
 
 
). The PCR products have AgeI
 
and EcoRI cutting sites before and after 
 
 
 
p85 cDNA, respec-
tively, and were inserted into a pCRII TOPO vector. The plas-
mids were digested with AgeI-EcoRI and ligated into an AgeI-
EcoRI–digested pTAT vector (provided by Dr. S. Dowdy) using
T4 ligase.
Purification of TAT fusion proteins was performed as de-
scribed (22, 23). Briefly, TAT-protein was purified by sonication
of high expressing BL21 cells in 10 ml of buffer Z (8 M urea, 20
mM Hepes, pH 8.0, 100 mM NaCl). Cellular lysates were re-
solved by centrifugation, loaded onto a 5-ml Ni-NTA column in
buffer Z, washed, and eluted with imidazole in buffer Z sequen-
tially in 100, 250, and 500 mM concentrations. Urea and imida-
zole were removed from the resultant protein solution using a
low volume, 10,000 MWCO Slide-A-Lyzer dialysis cassette.
Each fusion protein was flash-frozen at 
 
 
 
80
 
 
 
C.
 
Mice.
 
Male C57BL/6 mice, 6–8-wk-old, were purchased
from the Jackson Laboratory and housed in a pathogen-free bio-
hazard level 2 facility maintained by The University of Chicago
Animal Resources Center. The studies reported here conform to
the principles outlined by the Animal Welfare and the National
Health Services guidelines for the care and use of animals in bio-
medical research.
In protocols detailed below, animals receive i.p. TAT-
 
 
 
p85 or
control injection. The animals receiving injection of TAT-
 
 
 
p85
or control proteins (His-
 
 
 
p85 or TAT-GFP) were assigned ran-
domly to the experimental groups consisting of six animals each.
In preliminary studies, we demonstrated that TAT protein vector
(administered as TAT-GFP) had no effect on OVA-induced air-
way inflammation and airway responsiveness versus saline buffer
control.
 
Flow Cytometric Analysis of the TAT Fusion Protein Transduction
into Blood Leukocytes.
 
Either TAT-
 
 
 
p85 or control protein lack-
ing the TAT PTD was labeled with FITC (Sigma-Aldrich) ac-
cording to manufacturer’s instructions. Mice were killed and
blood was aspirated by cardiac puncture into a heparinized syringe
for isolation of whole-blood leukocytes at specified times after i.p.
injection of TAT-
 
 
 
p85 or control 
 
 
 
p85 protein. Whole-blood
leukocytes were isolated by hypotonic lysis of RBC. Isolated leu-
kocytes were resuspended in calcium- and magnesium-free HBSS,
pH 6.8, containing 1% BSA. The pH of the sheath fluid of the
flow cytometer was adjusted to 6.8 to quench FITC fluorescence
on the outside of the cell (24), and at least 10,000 cells were ana-
lyzed on a FACScan (Becton Dickinson).
 
Western Blot Analysis of the Uptake of TAT-
 
 
 
p85 into Lung Tis-
sue and the Efficacy of TAT-
 
 
 
p85 Protein Transduction on FMLP-
induced PKB Phosphorylation in Lung Tissues.
 
To examine the up-
take of TAT-
 
 
 
p85 into the lung, lungs were excised from mice
at indicated times after i.p. administration of TAT-
 
 
 
p85 (10 mg/
kg). To examine the efficacy of TAT-
 
 
 
p85 transduction, TAT-
 
 
 
p85 (10 mg/kg) or control protein was administered i.p. at the
indicated times before administration of FMLP. Animals were
lightly anesthetized with 4.4 mg/kg i.p. xylazine and 65 mg/kg
i.p. ketamine (25) and then challenged intranasally with 100 
 
 
 
l of
10
 
 
 
5
 
 M FMLP dissolved in PBS through 24-g catheter. 15 min
after FMLP instillation, mice were anesthetized with 30 mg/kg
i.p. xylazine and 80 mg/kg i.p. ketamine, and lungs then were
perfused through the right ventricle with 5 ml of PBS. The lungs
were excised, rinsed in PBS, blotted dry, snap frozen in liquid ni-
trogen, and stored at 
 
 
 
80
 
 
 
C. For preparation of whole-lung cell
extracts, 10 mg of ground lung tissue was resuspended in 500 
 
 
 
l
of lysis buffer (10 mM Tris, pH 7.4, 5 mM MgCl
 
2
 
, 50 U/ml
DNase and RNase, 10 
 
 
 
g/ml each of leupeptin, aprotinin and
pepstatin, 1 mM PMSF, and then homogenized for 30 s at a
Figure 1. Purified proteins used in this study. (a) Structure of TAT-
 p85 fusion protein. Six His residues and the 11–amino acid TAT peptide
precede the NH2-terminal of the  p85 protein. The 11 amino acids of
TAT are the protein transduction domain (PTD). (b) Control  p85 protein
lacking the PTD. (c) TAT-GFP, a control protein lacking  p85.T
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speed of 15,000 rpm in an Ultra-Turrax homogenizer). After a
30-min incubation on ice, homogenates were centrifuged at
16,000 
 
g
 
 for 10 min. Protein concentrations were determined us-
ing the Bradford assay, the supernatants were mixed with Laem-
mli sample buffer, and boiled for 5 min. The samples were stored
at 
 
 
 
80
 
 
 
C.
Whole-lung cell extracts (30 
 
 
 
g) were subjected to SDS-
PAGE, using acrylamide gels under reducing condition (15 mA/
gel). Electrotransfer of proteins from the gels to polyvinylidene
fluoride membrane was achieved using a semidry system (400
mA, 60 min). The membrane was blocked with 1% BSA for 60
min, then incubated with 1/1000 anti-phosphorylated PKB Ab,
1/1000 anti-6His tag (Cell Signaling, Beverly, MA), or 1/1000
anti-PKB Ab diluted in Tris buffered saline with Tween-20
(TBST) overnight. The membranes then were washed three
times for 20 min with TBST. Donkey anti-rabbit IgG conjugated
with HRP was diluted 1/3000 in TBST and incubated with
polyvinylidene fluoride membrane for 60 min. The membrane
was again washed three times with TBST and assayed by an ECL
chemiluminescence system (Amersham).
 
Immunization and Airway Challenge with OVA.
 
Mice were
sensitized and challenged as described previously (26). Briefly,
mice were immunized with 10 
 
 
 
g of OVA and 1.125 mg of alu-
minum hydroxide (Imgect Alum; Pierce Chemical Co.) in 0.2 ml
of sterile saline i.p. on days 0, 7, and 14. On days 21–24, mice
were exposed to aerosolized OVA (1%) or saline for 40 min. To
examine the effect of TAT-
 
 
 
p85 on antigen-induced airway re-
actions, the animals received i.p. injection of TAT-
 
 
 
p85 or con-
trol 
 
 
 
p85 protein lacking TAT PTD (Fig. 1 b) every 12 h from
the first OVA challenge to the assessment of BAL, tissue, and air-
way responsiveness. For measurement of airway responsiveness,
animals also received TAT vehicle lacking 
 
 
 
p85 (Fig. 1 c). In ad-
ditional experiments, TAT fusion proteins were administered in-
tranasally to mice to assess their effect on airway inflammation af-
ter antigen challenge. 2 h before OVA challenge, mice received
intranasal administration of 50 
 
 
 
l of 0.3 or 1.0 mg/ml TAT-
 
 
 
p85 through a 24 g catheter.
 
Measurement of Airway Responsiveness to Methacholine.
 
Metha-
choline challenge was performed 24 h after the final dose of
OVA. Respiratory system resistance (Rrs) was measured through
a computer-controlled small-animal ventilator (SAV) (Flexivent;
SCIREQ) as described previously (27). Briefly, mice were anes-
thetized with 30 mg/kg xylazine and 80 mg/kg ketamine i.p.,
and the trachea was cannulated with an 18-gauge metal needle
connected to the SAV. Mechanical ventilation was applied, and
animals were ventilated quasisinusoidally at a frequency of 120
breaths/min at a tidal volume of 6 ml/kg. The expiratory valve of
the SAV allowed the animal to empty passively through a water
trap adjusted to maintain a positive end-expiratory pressure
(PEEP) of 2.0 cmH
 
2
 
O. In preliminary experiments, this PEEP
was shown to be optimal for the determination of methacholine-
induced effects on Rrs (27). Increasing doses of methacholine
(31.3 to 4,000 
 
 
 
g/ml) were infused through a jugular vein cathe-
ter at 5-min intervals.
 
Collection and Analysis of Bronchoalveolar Fluid Cells.
 
Airway
inflammation was assessed 24 h after the final antigen challenge
with OVA. BAL was performed by delivering 0.8 ml cold PBS
into the airway through a trachea cannula and gently aspirating
the fluid. The lavage was repeated three times to recover a total
volume of 2–3 ml. The cells were stained with Trypan blue to
determine viability and with Turk solution to obtain total nucle-
ated cell counts using a hemocytometer. Cytospin (Cytospin 2;
Shandon) slides were prepared from the BAL and were then
 
fixed and stained using Diff-Quick (Dade Diagnostics). Differen-
tial cell counts were determined by counting a minimum of 300
cells/slide using standard morphological criteria in a single-blind
method.
 
Measurement of Cytokine Levels in BAL.
 
The concentrations
of IL-4, IL-5, and IFN-
 
 
 
 in BAL fluid were measured using a
Mouse Th1/Th2 Cytokine CBA kit according to the manufac-
turer’s protocol (BD Biosciences). The detection limits were 5
pg/ml for IL-4, 5 pg/ml for IL-5, and 2.5 pg/ml for IFN-
 
 
 
.
 
Lung Histology.
 
Lungs removed from the chest cavity were
fixed by injection of 4% buffered paraformaldehyde into the tra-
cheal cannula at a pressure of 20 cm H
 
2
 
O and immersed in para-
formaldehyde for 24 h. Lobes were sectioned sagitally, embed-
ded in paraffin, cut into 5 
 
 
 
m sections, and stained with H&E
for histological analysis. Additional sections were stained with
alcian blue/PAS to identify mucus-containing cells. The severity
of peribronchial inflammation was graded semiquantitatively for
the following features: 0, normal; 1, few cells; 2, a ring of in-
flammatory cells 1 cell layer deep; 3, a ring of inflammatory cells
2–4 cells deep; 4, a ring of inflammatory cells of 
 
 
 
4 cells deep.
Figure 2. Kinetics of TAT- p85 transduction into whole-blood
leukocytes in mice measured by flow cytometry. Whole-blood leuko-
cytes were isolated at 0, 2, 6, 12, and 24 h after i.p. injection of FITC-
labeled TAT- p85 to determine time-course and specificity of trans-
membrane uptake of TAT- p85. Nonspecific cell-surface fluorescence
was quenched by resuspension in pH 6.8 HBSS. (a) Conjugated TAT-
 p85 demonstrates maximal transcellular uptake at 2 h and is progressively
diminished over 24 h. (b) FITC-conjugated control  p85 protein, which
lacks the HIV-TAT domain, demonstrates no change in fluorescence versus
after resuspension in pH 6.8 HBSS.T
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IL-5–induced Airway Eosinophil Accumulation. TAT- p85 (3
or 10 mg/kg) or a control  p85 protein (excluding TAT PTD)
was i.p. administered 2 h before challenge with IL-5. Animals
were anesthetized with 4.4 mg/kg xylazine and 65 mg/kg i.p.
ketamine (25) and then challenged intranasally with 100  l of 100
ng/ml IL-5 dissolved in PBS through a 24-g catheter. BAL was
performed 12 h after IL-5 instillation as described above.
Statistical Analysis. Variation between three or more groups
was analyzed using ANOVA followed by Fisher’s least protected
difference test. Statistical significance was claimed whenever
P   0.05.
Results
Kinetics and Efficacy of TAT- p85 Transduction. The
pharmacokinetics of in vivo TAT- p85 transduction were
evaluated in mouse blood leukocytes. Mice were injected
with 10 mg/kg fluorescein isothiocyanate (FITC)-labeled
TAT- p85 i.p. or control  p85 protein lacking TAT
PTD. Flow cytometry of whole-blood leukocytes isolated
2–24 h after i.p. injection demonstrated the presence of
TAT- p85. TAT- p85 was maximally expressed at 2–6 h,
and disappeared by 24 h (Fig. 2 a). The T1/2 for TAT- p85
was 12 h. By contrast, control  p85 protein lacking the
TAT transduction domain was undetectable in blood leu-
kocytes at any time (Fig. 2 b).
Western blot analysis of lung (Fig. 3 A), spleen, and liver
(unpublished data) extracts demonstrated that TAT- p85
was maximally transduced at 2 h after i.p. administration of
TAT- p85, and disappeared thereafter (Fig. 3 A). The in-
ability of detecting of TAT- p85 at 4–12 h after i.p. injec-
tion may be due to the lower sensitivity of the Western
blot than flow cytometry (see below). Intraperitoneal injec-
tion of TAT- p85 caused substantial inhibition of PKB
Figure 3. Western blot analysis of the uptake of TAT- p85 into lung
tissue and the efficacy of TAT- p85 protein transduction on FMLP-
induced PKB phosphorylation in lung tissues. (A) Transduction of TAT-
 p85 into the lung. Lungs were excised from mice at indicated times after
i.p. administration of TAT- p85 (10 mg/kg), and lung tissue extracts
were mixed with loading buffer and separated by SDS-PAGE, and
probed by anti-His antibody. (B) Western blot analysis of the effect of
TAT- p85 on FMLP-induced PKB phosphorylation in whole-lung
tissue. FMLP was instilled intranasally at 0, 2, 4, 6, 12, and 24 h after
administration of TAT- p85. Whole-lung cell extracts were prepared
and analyzed by Western blot with antiphosphorylation-specific PKB Ab
(top). Equivalency of loading was established for each lane with anti-PKB
Ab, which measures total PKB (phosphorylated and nonphosphorylated)
(bottom). Inhibition of PKB phosphorylation is maximal at 2–6 h, corre-
sponding to fluorescence data from Fig. 2. By 12 h, there is diminished
inhibition of PKB phosphorylation by TAT- p85. The result shown is
representative of three different experiments.
Figure 4. Effect of IP administration of
TAT- p85 on airway inflammation after
OVA sensitization and challenge. Analysis
of inflammatory cells from BAL fluid 24 h
after last OVA challenge. Positive ( ) and
negative ( ) controls are OVA and saline
challenged animals, respectively. These ani-
mals received no other treatment. OVA
challenge caused increased total cell count,
which is largely composed of eosinophils.
Increase in lymphocytes and neutrophils are
recorded on a different scale (see ordinate).
There was no effect on macrophage number.
Migration of eosinophils and lymphocytes is
blocked progressively with 3–10 mg/kg
TAT- p85 but unaffected by 10 mg/kg
 p85 lacking the TAT domain. TAT- p85
has no effect on the migration of neutro-
phils, which is minimal. Each bar represents
the mean   SEM of 4–6 mice. *P   0.05
and  **P    0.01 compared with positive
control group. ND, not detectable.
The numerical scores for the abundance of PAS-positive mucus-
containing cell in each airway were determined as follows: 0,
 0.5% PAS-positive cells; 1, 5–25%; 2, 25–50%; 3, 50–75%; 4,
 75% (28).T
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phosphorylation in lung homogenates. Intranasal instilla-
tion of 10 5 M FMLP caused PKB phosphorylation in lung
tissue extracts compared with vehicle PBS-stimulated con-
trols; PKB phosphorylation was inhibited to baseline at
2–12 h after i.p. injection of 10 mg/kg TAT- p85 (Fig. 3
B). A control  p85 protein absent the 11–amino acid TAT
(Fig. 1 b) had no inhibitory effect on PKB phosphorylation
(unpublished data). These results demonstrated that i.p. de-
livery of TAT- p85 fusion protein into mice was distrib-
uted into the lungs, and functionally suppressed PI3K-
induced PKB phosphorylation. Based on the half-life of
TAT- p85 in blood leukocytes, TAT- p85 was adminis-
tered every 12 h in the subsequent experiments involving
antigen challenge.
Effect of TAT- p85 on Antigen-induced Airway Inflamma-
tion. OVA inhalation significantly increased eosinophil
(P   0.01), lymphocyte (P   0.01), and neutrophil numbers
(P   0.05) in BAL fluid (Fig. 4). Eosinophils were absent
in BAL fluid collected from the saline challenged group.
After OVA challenge, the number of eosinophils in the
BAL fluid increased to 538   60   103 cells (P   0.01).
Treatment of animals with 3–10 mg/kg TAT- p85
blocked the migration of eosinophils 24 h after OVA chal-
lenge in concentration-dependent manner. Eosinophil
number decreased to 251   5   103/ml with 3 mg/kg of
TAT- p85 (P   0.05) and further decreased to 82.6  
37.0   103/ml at 10 mg/kg (P   0.01). By contrast, con-
trol  p85 protein lacking the TAT PTD has no inhibitory
effect on OVA-induced eosinophil count in BAL fluid.
BAL lymphocytes increased from 0.13   0.06   103/
ml for saline challenged control to 48.6   7.2   103/ml
24 h after OVA challenge (P   0.01, Fig. 4). TAT- p85
also blocked the increase in lymphocytes in the airway lu-
men after OVA challenge in concentration-dependent
manner. Lymphocytes number decreased to 12.6   5.3  
103 at 3 mg/kg (P   0.01) and 6.3   1.9   103/ml at 10
mg/kg TAT- p85 (P   0.01 vs. a  p85 control protein
treated group).
OVA challenge modestly increased neutrophil number
in BAL to 13.1   4.9   103/ml; neutrophil was not found
in saline-challenged mice. Unlike eosinophils or lympho-
cytes, OVA-induced airway neutrophilia was not blocked
by pretreatment with TAT- p85. Macrophage number in
BAL was neither affected by OVA challenge nor by pre-
treatment with TAT- p85.
Effect of TAT- p85 on IL-5-induced Inflammation. Fur-
ther studies were performed to determine the role of PI3K
in IL-5–induced eosinophil migration into airways. Eosin-
ophils were not detected in BAL fluid in nonsensitized
animals; 12 h after intranasal instillation of IL-5, the eo-
sinophil count in BAL fluid was 5.0   0.7   103/ml (P  
0.01, Fig. 5). Pretreatment of animals with TAT- p85
concentration dependently blocked BAL eosinophilia to
2.4   0.9   103 at 3 mg/kg TAT- p85 (P   0.05) and
0.9   0.103/ml at 10 mg/kg TAT- p85 (P   0.01).
Antigen-induced Th2 Cytokine Secretion in BAL Fluids.
To evaluate the role of Th2 cytokines in OVA-induced
airway responses, we measured the concentrations of IL-4
Figure 5. Effects of TAT- p85 on eosinophil accumulation in BAL
fluid 12 h after intranasal administration of IL-5. Cell counts were obtained
from animals receiving IL-5   either control  p85 (lacking TAT domain)
or TAT- p85. Eosinophils were not detectable in airways of animals before
challenge with IL-5. TAT- p85 blocked progressively the eosinophil
migration caused by IL-5.  p85 lacking the TAT domain was not different
from IL-5 alone. Accordingly, TAT- p85 blocks both IL-5 synthesis
(Fig. 6) as well as the chemotactic effects of IL-5 on eosinophils. Each bar
represents the mean   SEM of 4–6 mice. *P   0.05 and **P   0.01
compared with positive control group. ND, not detectable.
Figure 6. Effect of TAT- p85 on Th1 and Th2 cytokine secretion
after four OVA challenges on days 21, 22, 23, and 24. BAL fluids were
collected 24 h after the last OVA challenge. Positive ( ) and negative ( )
controls are OVA and saline challenged animals, respectively, without any
pretreatment. TAT- p85 reduces the level of Th2 cytokines, IL-4 and
IL-5, but has no effect on the Th1 cytokine IFN . Note difference in
scale on the ordinate. Each bar represents the mean   SEM of 4–6 mice.
**P   0.01 compared with positive control group. ND, not detectable.T
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and IL-5 in BAL fluid. OVA inhalation caused a significant
increase in the concentration of IL-4 and IL-5, which was
concentration dependently inhibited by TAT- p85. There
was no reduction of these Th2 cell cytokines in control
mice receiving  p85 lacking the TAT PTD (Fig. 6). OVA
challenge also increased the barest concentration of Th1
cytokine, INF- , a Th-1 cell cytokine, in BAL fluid.
TAT- p85 at 10 mg/kg had no inhibitory effect on INF- 
level in BAL fluid.
Effect of TAT- p85 on Airway Histology. OVA chal-
lenge induced inflammatory cell infiltration (largely eosino-
phils and mononuclear cells) in the lung interstitium around
the airways and pulmonary blood vessels (Fig. 7 A, 1 and 2).
Pretreatment with 3–10 mg/kg TAT- p85 blocked cell in-
filtration progressively at 24 h (Fig. 7, A 3 and B, left). Al-
though many mucus-containing epithelial cells were appar-
ent in OVA-challenged mice (Fig. 7 A, 4 and 5), very few
of these cells were detected in mice treated with 10 mg/kg
TAT- p85 (Fig. 7, A 6 and B, right).
Antigen-induced Airway Hyperresponsiveness. Antigen-
induced airway hyperresponsiveness to methacholine was
attenuated by TAT- p85 (Fig. 8). Rrs was comparable 24 h
after the last OVA challenge in each group before metha-
choline challenge (time zero). Sensitization with OVA
caused substantial increase in methacholine response com-
pared with mice receiving saline inhalation. TAT- p85,
but not  p85 absent the TAT transduction domain, inhib-
Figure 7. Histologic examination of lung tissues. (A) Representative sections of the lungs. The lung sections were obtained from saline- (1, 4) or OVA-
(2, 3, 5, 6) challenged mice in the absence (1, 2, 4, 5) or presence (3, 6) of TAT- p85 (10 mg/kg). Sections are stained with haematoxylin and eosin (1,
2, 3) for morphological analysis of inflammation and with alcian blue/PAS (4, 5, 6) for analysis of mucin-containing cells. Tissue was examined by light
microscopy (original magnification 400 ). Substantial inflammation and mucin production caused by OVA (2, 5) are blocked by TAT- p85 (3, 6); compare
with saline control (1, 4). (B) Semiquantitative analysis of the severity of peribronchial inflammation and the abundance of PAS-positive mucus-containing
cells. Total lung inflammation and PAS-positive cells were defined as the average of the scores as described in Materials and Methods. *P   0.05 and **P  
0.01 compared with positive control group.
Figure 8. Effect of TAT- p85 on antigen-induced airway hyperre-
sponsiveness to methacholine in immunized mice following four OVA
challenges on days 21, 22, 23 and 24. Airway responsiveness was mea-
sured 24 h after the last OVA challenge. Positive ( ) and negative ( )
controls are OVA and saline challenged animals, respectively, without
any pretreatment.  p85 lacking the TAT domain has no attenuating
effect on antigen challenge in immune sensitized mice ( ). By contrast,
10 mg/kg TAT- p85 ( ) blocked methacholine responsiveness in sen-
sitized animals to control level ( ), i.e., the response was comparable to
that of sensitized, saline-challenged animals. Each bar represents the
mean   SEM of 4–6 mice. *P   0.05 and **P   0.01 compared with
positive control group.T
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ited the augmented dose–response curve to methacholine
in a dose-dependent manner. In a subsequent study, we
demonstrated that TAT vehicle alone had no effect on the
baseline airway responsiveness to methacholine. Hence,
blockade of OVA-induced airway response to methacho-
line challenge was not caused by TAT protein in the ab-
sence of  p85.
Discussion
The objective of this investigation was to determine the
potential role of PI3K in antigen-induced airway inflam-
mation, Th2 cytokine secretion, and airway hyperrespon-
siveness in mice. Our results show that TAT- p85 attenu-
ates antigen-induced airway infiltration of eosinophils and
lymphocytes in a concentration-dependent manner, re-
duces the number of mucus-containing cells in the airway
lumen, reduces Th2 cytokine concentrations in BAL, and
blocks airway hyperresponsiveness to methacholine. These
findings suggest that PI3K signaling likely has a regulatory
role in antigen-induced airway inflammation and hyperre-
sponsiveness in mice.
The Th2 cytokine, IL-4, regulates allergic inflammation
by promoting Th2 cell differentiation (29, 30), IgE synthe-
sis and its receptor up-regulation (31, 32), VCAM-1 ex-
pression (33), and airway hypersecretion (34). Another Th2
cytokine, IL-5, promotes eosinophilic inflammation and
infiltration into airways (35, 36). Our data demonstrate that
blockade of PI3K signaling by i.p. administration of TAT-
 p85 reduces secretion of Th2 cytokines (IL-4 and IL-5),
but has no effect on the secretion of the Th-1 cytokine,
IFN , in the BAL fluid. These data suggest that PI3K regu-
lates, in part, the balance between Th1 and Th2 lympho-
cytes (Fig. 6).
Although the mechanistic relationship between eosino-
philic inflammation and airway hyperresponsiveness has not
been established, eosinophils and their granular contents can
cause airway smooth muscle contraction (7, 37, 38). Many
inflammatory mediators attract and activate eosinophils
through signal transduction pathways involving the enzyme,
PI3K. In this study, TAT- p85 administration blocked anti-
gen-induced both airway infiltration of eosinophils and air-
way hyperresponsiveness. Blockade of eosinophilic infiltra-
tion into airway can be caused by: (a) decreased release of
eosinophils from bone marrow, (b) decreased eosinophil ad-
hesion to endothelial cells and subsequent blockade of che-
motaxis, or (c) decreased Th2 cytokine secretion. Palframan
et al. (12) reported that wortmannin inhibited IL-5–induced
release of eosinophils from perfused bone marrow, as well as
selective eosinophil chemokinesis in vitro (12). We have
demonstrated previously that the pharmacological inhibition
of PI3K by LY294002 or wortmannin blocks eosinophil ad-
hesion to ICAM-1 caused by IL-5 in vitro (39). In this
study, TAT- p85 blocked Th2 cytokine secretion after an-
tigen challenge (Fig. 6) and IL-5–induced eosinophil migra-
tion (Fig. 5), suggesting that PI3K is involved in cytokine-
induced eosinophil migration. Our data are consistent with
the results obtained in studies reported by others showing
that PI3K inhibition blocks the increased number of eosino-
phils in OVA-challenged mice (40). Other investigations
have shown that PI3K inhibition blocks eosinophil degranu-
lation in vitro (41) and in vivo (40, 41). In our report, de-
creased airway hyperresponsiveness corresponded to block-
ade of infiltration of eosinophils into the conducting airways.
In contrast to eosinophils, TAT- p85 had no effect on
neutrophil migration into the airway after antigen chal-
lenge. It has been reported that class IB PI3K -deficient
neutrophils have severe defects in migration and respiratory
burst activity in response to heterotrimeric G protein–cou-
pled receptor agonists and chemotactic agents (42). Thus,
class IB PI3K  rather than class IA PI3K may regulate neu-
trophil migration.
The effects of transduction of TAT- p85 in decreasing
airway hyperresponsiveness and inflammation appear to be
fully specific to  p85 domain of the TAT. Treatment with
 p85 lacking the TAT domain had no effect on airway re-
sponsiveness or inflammatory cell migration after allergen
challenge. Likewise, TAT-GFP, which transmits the HIV-
TAT domain, but not the  p85 domain, had no effect on
antigen-induced airway inflammation and methacholine-
induced airway responsiveness versus saline controls.
A potential strategy for treatment asthma is to develop
methods for blocking the signal transduction pathways
causing inflammatory cell activation. A variety of PI3K ef-
fectors, such as PDK-1, PKB, p70 S6 kinase (p70S6K), and
protein kinase C (PKC), and eliminators, such as PTEN
(40), have been reported, and some of these were reported
as critical signal transduction molecules in the pathogenesis
of asthma. The p70S6K inhibitors, rapamycin and its ana-
logue, were reported to inhibit antigen-induced airway in-
flammation and airway responsiveness in mice (43, 44).
Rapamycin also blocked allergen-driven T cell prolifera-
tion and IL-5 production in PBMCs (43). Cellular PKC
activity was increased in asthmatic patients (45), and in-
creased expression and activation of PKC , which is phos-
phorylated in the activation loop site by PDK-1 (46, 47),
correlated with antigen-induced late asthmatic responses
(48). PTEN blocks the action of PI3K by dephosphorylat-
ing the signal lipid, PIP3. Intratracheal administration of
adenoviruses carrying PTEN cDNA significantly reduced
IL-4, IL-5, and eosinophil cationic protein levels in BAL
fluids after OVA inhalation (40). Although the PI3K inhib-
itor, wortmannin, has been shown to inhibit antigen-
induced airway hyperresponsiveness in mouse and guinea
pigs (40, 41), wortmannin also exhibits an inhibitory effect
on group IV-PLA2 (49), phospholipase D (50), or myosin
light chain kinase (51). Accordingly, specific blockade of
the PI3K signaling rather than a pharmacological inhibitor
may be therapeutically more specific in airway inflamma-
tory disease. In 1999, Dowdy et al. (20) reported the deliv-
ery of a biologically active protein into the mouse without
signs of gross neurological problems or systemic distress. In
this study, TAT- p85 had a marked effect on experimental
antigen–induced asthmatic reactions, and there were noT
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apparent adverse effects on BAL cell viability as assessed by
trypan blue dye, histological change of the lung, or physio-
logical airway smooth muscle response to methacholine in
TAT- p85-treated mice. These results suggest possibilities
for the development of protein therapies targeted to the
specific pathways for bronchial asthma.
Our data, which link specific physiological events, i.e.,
airway hyperresponsiveness to inflammatory cell migration
(i.e., eosinophils), also suggests that blockade of the latter
during immune sensitization prevents the development of
airway hyperresponsiveness. These data suggest that inter-
vention with TAT- p85 protein could possibly be effica-
cious in preventing the development of airway hyperre-
sponsiveness in humans. However, rodents do not develop
the “human” asthma, and blockade of airway hyperrespon-
siveness in these studies was achieved in mice newly sensi-
tized with antigen from the naïve state. Hence, it is not
certain whether long established human asthma would re-
spond comparably. It is important to acknowledge specific
limitations of our findings. Our data were obtained in mice
with experimentally induced antigen-mediated airway hy-
perresponsiveness. Although the histological changes in
these airways resemble those of human asthma, these data
cannot be extrapolated to the human state. Nonetheless,
these data suggest both a possible pathogenetic mechanism
and means for therapeutic intervention in human asthmatic
states that is worthy of further consideration.
We conclude that blockade of PI3K in antigen sensitized
animals reduces Th2 cytokine levels in the BAL, blocks
eosinophil and lymphocyte migration into airways and con-
sequent airway hyperresponsiveness to methacholine. Ac-
cordingly, PI3K may have a potential role in the immune
regulation of Th2-mediated airway hyperresponsiveness.
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